Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

NASDAQ:SMMT

Summit Therapeutics Inc.

Last Close

4.51

17/05 20:00

Market Cap

2.72B

Beta: −1.02

Volume Today

1.18M

Avg: 2.06M

PE Ratio

−1.63

PFCF: −51.96

Financials Not Available